LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 445

Search options

  1. Article ; Online: Yes We Can (Use Nirmatrelvir/Ritonavir Even in High Immunological Risk Patients Treated with Immunosuppressive Drugs)!

    Lemaitre, Florian

    Clinical pharmacokinetics

    2022  Volume 61, Issue 8, Page(s) 1071–1073

    MeSH term(s) HIV Protease Inhibitors/therapeutic use ; Humans ; Immunosuppressive Agents/adverse effects ; Ritonavir/therapeutic use
    Chemical Substances HIV Protease Inhibitors ; Immunosuppressive Agents ; Ritonavir (O3J8G9O825)
    Language English
    Publishing date 2022-07-23
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 197627-8
    ISSN 1179-1926 ; 0312-5963
    ISSN (online) 1179-1926
    ISSN 0312-5963
    DOI 10.1007/s40262-022-01158-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Has the Time Come for Systematic Therapeutic Drug Monitoring of First-Line and WHO Group A Antituberculosis Drugs?

    Lemaitre, Florian

    Therapeutic drug monitoring

    2021  Volume 44, Issue 1, Page(s) 133–137

    Abstract: Abstract: Tuberculosis (TB) is a major global health issue, with approximately 10 million people being infected each year, and is the leading cause of mortality from infectious disease, with 1.5 million deaths a year. Optimal TB treatment requires a ... ...

    Abstract Abstract: Tuberculosis (TB) is a major global health issue, with approximately 10 million people being infected each year, and is the leading cause of mortality from infectious disease, with 1.5 million deaths a year. Optimal TB treatment requires a combination of drugs for an adequate treatment duration owing to persistent organisms, hardly accessible infection sites, and a high risk of resistance selection. Long-term therapy increases the risk of patients' loss of adherence, adverse drug reactions, and drug-drug interactions, potentially leading to treatment failure. The high interpatient variability of TB drug exposure is another point eliciting interest in therapeutic drug monitoring (TDM) to optimize treatment. Studies reporting clinically relevant exposure thresholds, which might be proposed as targets toward treatment personalization, are discussed. Practical TDM strategies have also been reported to circumvent issues related to delayed drug absorption and the need for multiple samples when evaluating the area under the curve of drug concentrations. The need for treatment individualization is further emphasized because of the development of multidrug-resistant TB or extensively drug-resistant TB. Finally, the willingness to shorten the treatment duration while maintaining success is also a driver for ensuring adequate exposure to TB drugs with TDM. The aim of the present review was to underline the role of TDM in drug-susceptible TB and World Health Organization group A TB drugs.
    MeSH term(s) Antitubercular Agents/therapeutic use ; Drug Monitoring ; Extensively Drug-Resistant Tuberculosis/drug therapy ; Humans ; Mycobacterium tuberculosis ; Tuberculosis, Multidrug-Resistant/drug therapy ; World Health Organization
    Chemical Substances Antitubercular Agents
    Language English
    Publishing date 2021-12-02
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 424443-6
    ISSN 1536-3694 ; 0163-4356
    ISSN (online) 1536-3694
    ISSN 0163-4356
    DOI 10.1097/FTD.0000000000000948
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: [No title information]

    Lemaitre, Florian

    Therapie

    2020  Volume 76, Issue 4, Page(s) 317–318

    Title translation Médiateurs de l’inflammation : le chaînon manquant de la variabilité pharmacocinétique ?
    MeSH term(s) Humans ; Inflammation ; Inflammation Mediators
    Chemical Substances Inflammation Mediators
    Language French
    Publishing date 2020-12-02
    Publishing country France
    Document type Editorial
    ZDB-ID 603474-3
    ISSN 1958-5578 ; 0040-5957
    ISSN (online) 1958-5578
    ISSN 0040-5957
    DOI 10.1016/j.therap.2020.12.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: TDM Is Alive and Kicking!

    Lemaitre, Florian / Hesselink, Dennis A

    Therapeutic drug monitoring

    2022  Volume 45, Issue 1, Page(s) 3–5

    Language English
    Publishing date 2022-09-23
    Publishing country United States
    Document type Journal Article
    ZDB-ID 424443-6
    ISSN 1536-3694 ; 0163-4356
    ISSN (online) 1536-3694
    ISSN 0163-4356
    DOI 10.1097/FTD.0000000000001034
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: The Role of Intra-Patient Variability of Tacrolimus Drug Concentrations in Solid Organ Transplantation: A Focus on Liver, Heart, Lung and Pancreas.

    Coste, Gwendal / Lemaitre, Florian

    Pharmaceutics

    2022  Volume 14, Issue 2

    Abstract: Tacrolimus, the keystone immunosuppressive drug administered after solid organ transplantation, presents a narrow therapeutic index and wide inter- and intra-patient pharmacokinetic variability (IPV). The latter has been fairly studied in kidney ... ...

    Abstract Tacrolimus, the keystone immunosuppressive drug administered after solid organ transplantation, presents a narrow therapeutic index and wide inter- and intra-patient pharmacokinetic variability (IPV). The latter has been fairly studied in kidney transplantation, where it could impact outcomes. However, literature about other transplanted organ recipients remains inconclusive. This review aimed at summarizing the evidence about the IPV of tacrolimus concentrations outside of the scope of kidney transplantation. First, factors influencing IPV will be presented. Then, the potential of IPV as a biomarker predictive of graft outcomes will be discussed in liver, heart, lung and pancreas transplantation. Lastly, strategies to reduce IPV will be reviewed, with the ultimate objective being ready-to-implement solutions in clinical practice by transplantation professionals.
    Language English
    Publishing date 2022-02-08
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527217-2
    ISSN 1999-4923
    ISSN 1999-4923
    DOI 10.3390/pharmaceutics14020379
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Possible causes of narcosis-like symptoms in freedivers.

    Lemaître, Frédéric / Costalat, Guillaume / Allinger, Jérémie / Balestra, Costantino

    Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc

    2023  Volume 50, Issue 2, Page(s) 85–93

    Abstract: During deep-sea freediving, many freedivers describe symptoms fairly similar to what has been related to inert gas narcosis in scuba divers. This manuscript aims to present the potential mechanisms underlying these symptoms. First, known mechanisms of ... ...

    Abstract During deep-sea freediving, many freedivers describe symptoms fairly similar to what has been related to inert gas narcosis in scuba divers. This manuscript aims to present the potential mechanisms underlying these symptoms. First, known mechanisms of narcosis are summarized while scuba diving. Then, potential underlying mechanisms involving the toxicity of gases (nitrogen, carbon dioxide and oxygen) are presented in freedivers. As the symptoms are felt during ascent, nitrogen is likely not the only gas involved. Since freedivers are frequently exposed to hypercapnic hypoxia toward the end of the dive, it is proposed that carbon dioxide and oxygen gases both play a major role. Finally, a new "hemodynamic hypothesis" based on the diving reflex is proposed in freedivers. The underlying mechanisms are undoubtedly multifactorial and therefore require further research and a new descriptive name. We propose a new term for these types of symptoms: freediving transient cognitive impairment.
    MeSH term(s) Humans ; Stupor/complications ; Carbon Dioxide/toxicity ; Inert Gas Narcosis/etiology ; Diving/adverse effects ; Nitrogen ; Oxygen
    Chemical Substances Carbon Dioxide (142M471B3J) ; Nitrogen (N762921K75) ; Oxygen (S88TT14065)
    Language English
    Publishing date 2023-06-11
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1154414-4
    ISSN 1066-2936
    ISSN 1066-2936
    DOI 10.22462/01.01.2023.38
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Pharmacokinetic Interactions Between Abiraterone, Apalutamide, Darolutamide or Enzalutamide and Antithrombotic Drugs: Prediction of Clinical Events and Review of Pharmacological Information.

    Boujonnier, François / Lemaitre, Florian / Scailteux, Lucie-Marie

    Cardiovascular drugs and therapy

    2023  

    Abstract: Purpose: Abiraterone, apalutamide, darolutamide and enzalutamide are second-generation hormone therapies used for advanced prostate cancer; the majority of patients receiving these treatments are elderly, poly-medicated patients. Since their first ... ...

    Abstract Purpose: Abiraterone, apalutamide, darolutamide and enzalutamide are second-generation hormone therapies used for advanced prostate cancer; the majority of patients receiving these treatments are elderly, poly-medicated patients. Since their first market authorizations, their pharmacokinetic (PK) characteristics are increasingly well known. A potential risk of drug-drug interaction (DDI), especially with cardiovascular drugs, needs to be considered. In the case of antithrombotics, treatment imbalance can lead to severe consequences.
    Objectives: To describe PK profiles of hormone therapies and antithrombotics and to predict DDIs and potentially related clinical events.
    Methods: PK profiles (CYP450 and P-gp substrate, inducer or inhibitor) are described by cross-referencing data sources (summary of product characteristics, European public assessment reports, PubMed database, Micromedex
    Results: Antithrombotics are mainly metabolized by CYP 2C9, 2C19 or 3A4. For abiraterone (CYP 2C8, 2D6 inhibitor) and darolutamide (CYP 3A4 inducer), no interaction was identified with antithrombotics. For apalutamide (CYP 2C9, 2C19, 3A4 and P-gp inducer) and enzalutamide (CYP 2C9, 2C19, 3A4 inducer and P-gp inhibitor), several PK interactions were identified with antithrombotics, which could lead to various clinical events (haemorrhage or thromboembolism).
    Conclusion: Numerous interactions are expected between enzalutamide or apalutamide and antithrombotics, for which management should be deployed on a case-by-case basis. PK and pharmaco-epidemiological studies could shed light on whether or not there are clinically significant events related to DDIs with antithrombotics.
    Language English
    Publishing date 2023-05-01
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 639068-7
    ISSN 1573-7241 ; 0920-3206
    ISSN (online) 1573-7241
    ISSN 0920-3206
    DOI 10.1007/s10557-023-07453-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Euthanasie et don d’organes.

    Lemaitre, F / Hubert, M

    Revue medicale de Bruxelles

    2018  Volume 38, Issue 6, Page(s) 470–473

    Abstract: We report the case of a 61 year's old patient with an amyotrophic lateral sclerosis who donates his organs after being euthanised. We recall here the strict legal framework of euthanasia and organ donation in Belgium. We also highlight the absolute need ... ...

    Title translation Euthanasia and organ donation.
    Abstract We report the case of a 61 year's old patient with an amyotrophic lateral sclerosis who donates his organs after being euthanised. We recall here the strict legal framework of euthanasia and organ donation in Belgium. We also highlight the absolute need to respect the ethical principles essential for the correct implementation of both procedures.
    Language French
    Publishing date 2018-01-09
    Publishing country Belgium
    Document type English Abstract ; Journal Article
    ZDB-ID 760217-0
    ISSN 0035-3639
    ISSN 0035-3639
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Perspective on the Use of Limited Sampling Strategies to Assess Drug Exposure in the Era of Microsampling.

    Tron, Camille / Lemaitre, Florian

    Therapeutic drug monitoring

    2021  Volume 43, Issue 6, Page(s) 812–813

    MeSH term(s) Blood Specimen Collection ; Humans ; Specimen Handling
    Language English
    Publishing date 2021-08-30
    Publishing country United States
    Document type Letter
    ZDB-ID 424443-6
    ISSN 1536-3694 ; 0163-4356
    ISSN (online) 1536-3694
    ISSN 0163-4356
    DOI 10.1097/FTD.0000000000000923
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Mega randomized clinical trials: a definitive solution or a double-edged sword?

    Lemaitre, Florian / Laviolle, Bruno

    European journal of clinical pharmacology

    2021  Volume 78, Issue 2, Page(s) 305–306

    MeSH term(s) COVID-19/drug therapy ; Humans ; Pandemics ; Randomized Controlled Trials as Topic/methods ; Randomized Controlled Trials as Topic/standards ; Research Design ; SARS-CoV-2 ; Sample Size
    Language English
    Publishing date 2021-10-14
    Publishing country Germany
    Document type Letter
    ZDB-ID 121960-1
    ISSN 1432-1041 ; 0031-6970
    ISSN (online) 1432-1041
    ISSN 0031-6970
    DOI 10.1007/s00228-021-03230-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top